Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document no.: LAB041402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 42 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc39
Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc43
Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 15; Document no.: LAB041501-01 ESR In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc29
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 17; Document no.: LAB041501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc45
Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 14; Document no.: LAB041401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc25
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 15; Document no.: LAB041401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST rapid review report) https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc44
Miller, L; Mueller, M. What are the harmful/adverse effects of multiple doses of COVID-19 mRNA vaccines? 2022 Jan 25. Document no.: EOC220103 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 65 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc429
Badea, A; Reeder, B; Groot, G; Miller, L; Mueller, M. What are the harmful/adverse effects of multiple doses of COVID-19 mRNA vaccines? 2022 Feb 04, Document no.: EOC220103 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 10 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc439
Fox, L; Miller, L. What is known about hybrid immunity to COVID-19? 2022 May 18, Document no.: INF220501 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 41 p. (CEST evidence search report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc480
Groot, G; Reeder, B; Muhajarine, N; Lee, S; Badea, A; Jagwani, M; Fox, L; Miller, L. What is known about hybrid immunity to COVID-19? 2022 Jun 06, Document no.: INF220501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2022. 11 p. (CEST rapid review report). https://covid19evidencereviews.saskhealthauthority.ca/en/permalink/coviddoc498
